Current Market Access to Avsola, Inflectra and Remicade
While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.
NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 7/12/21.